China’s Sinovac’s COVID-19 vaccine is coming under greater public scrutiny as the Thai government procures millions more doses. The government of Prime Minister Gen Prayuth Chan-o-cha has already imported 6 million doses of the Sinovac vaccine – (also known as CoronaVac) from China.
The amount also includes 500,000 jabs donated by the Chinese government. In June, Thailand’s government will take delivery of another 3 million doses of China’s Sinovac vaccine. Most Thais who have been vaccinated received Sinovac, which will soon be administered to several million more.
As a result, the Thai public is keen to find out more about this inactivated vaccine.
Data from a clinical trial in Brazil show Sinovac was 50.4% effective at preventing symptomatic infections overall. However, it was 78 per cent effective in preventing mild to serious cases that need hospitalisation.
Meanwhile, results of a Sinovac trial in Turkey showed 83.5 per cent protection against symptomatic COVID-19 and 100 per cent protection against hospitalisation.
Earlier this month, a study on the vaccine’s results on millions of recipients in Chile showed Sinovac was 65.3 per cent effective in preventing symptomatic COVID-19. Its efficacy rate was 87 per cent in preventing hospitalisation, 90.3 per cent in preventing admission to an intensive care unit (ICU), and 86 per cent in preventing death. This latest data has sparked concern that the vaccine does not offer complete protection against death from COVID.
A passport to overseas travel?
Thailand is now issuing international vaccination certificates on request to facilitate travel for people who are fully inoculated. But this certificate is currently useless for Sinovac recipients who want to go to European Union countries for tourism or non-essential travel.
The EU only recognizes vaccines approved by its own regulator or by the World Health Organization (WHO) – namely the AstraZeneca, Johnson & Johnson, Moderna, Pfizer-BioNTech and Sinopharm.
At present, the EU and WHO are still reviewing China’s Sinovac.
However, Thai travelers are likely to get relief from the EU’s travel list of safe countries. Based on criteria reported by foreign media, Thailand should have no problem qualifying for the list because the Kingdom’s COVID-19 notification rate – the number of new cases per 100,000 people recorded over the previous 14 days — is far below the reported benchmark of 75.
At present, Thailand has only acquired AstraZeneca and Sinovac for protection against COVID-19. However, the Johnson & Johnson and Moderna vaccines have also been registered in Thailand. Meaning that more choices should be on the way.
Public Health Minister Anutin Charnvirakul revealed this week that the government is in advanced talks with Pfizer for its vaccine, which has been marked safe for children aged 12 and older.
“We are now in the early stage of negotiations for Russia’s Sputnik V [vaccine],” he added.
And talks with Johnson & Johnson’s are being conducted by the Disease Control Department with a timeline to import doses by the final quarter of this year.
Meanwhile, Sinovac has been urgently procured to help control the ongoing serious outbreak of COVID-19 transmissions in Thailand, said Anutin.
However, locally made AstraZeneca remains Thailand’s vaccine of choice, he added.
“The local manufacturer [Siam Bioscience] will deliver the vaccine from June. If the factory in Thailand has any problems, it will have to procure AstraZeneca vaccine for us from elsewhere.”
People in Thailand who prefer to turn to the private sector for jabs are likely to be given the Moderna vaccine. This is expected to be available by the last quarter of 2021 through private hospitals supplied by the Government Pharmaceutical Organization.
Dr Krittavith Lertutsahakul, chief executive officer of Vimut Hospital’s operator, said he expected the first batch of Moderna COVID-19 vaccine to reach Thailand in October.
5,722 , 8